News >

FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 15, 2018

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x